180 related articles for article (PubMed ID: 37704069)
1. Antisense oligonucleotides targeting a NOTCH3 mutation in male mice ameliorate the cortical osteopenia of lateral meningocele syndrome.
Canalis E; Mocarska M; Schilling L; Jafar-Nejad P; Carrer M
Bone; 2023 Dec; 177():116898. PubMed ID: 37704069
[TBL] [Abstract][Full Text] [Related]
2. Use of antisense oligonucleotides to target Notch3 in skeletal cells.
Canalis E; Carrer M; Eller T; Schilling L; Yu J
PLoS One; 2022; 17(5):e0268225. PubMed ID: 35536858
[TBL] [Abstract][Full Text] [Related]
3. The lateral meningocele syndrome mutation causes marked osteopenia in mice.
Canalis E; Yu J; Schilling L; Yee SP; Zanotti S
J Biol Chem; 2018 Sep; 293(36):14165-14177. PubMed ID: 30042232
[TBL] [Abstract][Full Text] [Related]
4. Induction of a NOTCH3 Lehman syndrome mutation in osteocytes causes osteopenia in male C57BL/6J mice.
Canalis E; Yee SP; Economides AN; Schilling L; Yu J
Bone; 2022 Sep; 162():116476. PubMed ID: 35760307
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides targeting
Canalis E; Grossman TR; Carrer M; Schilling L; Yu J
J Biol Chem; 2020 Mar; 295(12):3952-3964. PubMed ID: 31992595
[TBL] [Abstract][Full Text] [Related]
6. An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice.
Yu J; Siebel CW; Schilling L; Canalis E
J Cell Physiol; 2020 Jan; 235(1):210-220. PubMed ID: 31188489
[TBL] [Abstract][Full Text] [Related]
7. The Skeleton of Lateral Meningocele Syndrome.
Canalis E
Front Genet; 2020; 11():620334. PubMed ID: 33519922
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1.
Ait Benichou S; Jauvin D; De Serres-Bérard T; Bennett F; Rigo F; Gourdon G; Boutjdir M; Chahine M; Puymirat J
Hum Gene Ther; 2022 Aug; 33(15-16):810-820. PubMed ID: 35794764
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotides Targeting Jagged 1 Reduce House Dust Mite-induced Goblet Cell Metaplasia in the Adult Murine Lung.
Carrer M; Crosby JR; Sun G; Zhao C; Damle SS; Kuntz SG; Monia BP; Hart CE; Grossman TR
Am J Respir Cell Mol Biol; 2020 Jul; 63(1):46-56. PubMed ID: 32176858
[TBL] [Abstract][Full Text] [Related]
10. Sustained Notch2 signaling in osteoblasts, but not in osteoclasts, is linked to osteopenia in a mouse model of Hajdu-Cheney syndrome.
Zanotti S; Yu J; Sanjay A; Schilling L; Schoenherr C; Economides AN; Canalis E
J Biol Chem; 2017 Jul; 292(29):12232-12244. PubMed ID: 28592489
[TBL] [Abstract][Full Text] [Related]
11. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
12. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
Kim TW; Kim KS; Seo JW; Park SY; Henry SP
J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the efficacy of purchased antisense oligonucleotides to reduce mouse and human tau
Vemula P; Schoch KM; Miller TM
Front Mol Neurosci; 2023; 16():1320182. PubMed ID: 38192302
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
16. Lateral meningocele (Lehman) syndrome: A child with a novel NOTCH3 mutation.
Ejaz R; Qin W; Huang L; Blaser S; Tetreault M; Hartley T; Boycott KM; Carter MT;
Am J Med Genet A; 2016 Apr; 170A(4):1070-5. PubMed ID: 26754023
[TBL] [Abstract][Full Text] [Related]
17. Effects of combinations of gapmer antisense oligonucleotides on the target reduction.
Yanagidaira M; Yoshioka K; Nagata T; Nakao S; Miyata K; Yokota T
Mol Biol Rep; 2023 Apr; 50(4):3539-3546. PubMed ID: 36787053
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA.
Laptev AV; Lu Z; Colige A; Prockop DJ
Biochemistry; 1994 Sep; 33(36):11033-9. PubMed ID: 8086420
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
20. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice.
Kaufmann B; de Los Reyes Jiménez M; Booshehri LM; Onyuru J; Leszczynska A; Uri A; Michel S; Klar R; Jaschinski F; Feldstein AE; Broderick L; Hoffman HM
J Immunol; 2023 Jul; 211(2):287-294. PubMed ID: 37256266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
